Ophthalmology Clinical Trials

Updated 9/10/14

Contact Eliza Dubose at (984) 974-2057 or Sandy Barnhart, MPH at (919) 843-0076 for details regarding clinical trials in the UNC Department of Ophthalmology.


Cornea Clinical Trials - Ongoing Recruitment

Dry Eye/Reliability and Validity of the Dry Eye Symptom Severity Score (PI: Davis)

 

108 patients with dry eye and 50 control subjects are needed.  Patients will be asked to complete two symptom questionnaires, the Dry Eye Symptom Severity Score (DESSS) and the Ocular Surface Disease Index (OSDI), and participate in an exam of the cornea.  There will be a two week follow-up, at which point the DESSS will be completed for repeat reliability.


Glaucoma Clinical Trials - Ongoing Recruitment

None currently


Neuro-Ophthalmology Clinical Trials - Ongoing Recruitment

None currently


Oculoplastics Clinical Trials - Ongoing Recruitment

None currently


Pediatric Clinical Trials - Ongoing Recruitment

None currently


Retina Clinical Trials - Ongoing Recruitment

Diabetic Macular Edema / Diabetic Retinopathy Clinical Research Network (PI: Garg)

DRCR V: Treatment for Central-Involved Diabetic Macular Edema in Eyes with Very Good Visual Acuity

This is a 2 year study comparing laser, observation, and injections for treatment of            Diabetic Macular Edema in patients with vision of 20/25 or better.  Patients will be           randomly assigned to one of the three groups for the duration of the study.

DRCR AA: Peripheral DR Lesions on Ultrawide-field Fundus Images and Risk of Diabetic Retinopathy Worsening Over Time

This is a 4 year study that will be obtaining ultrawide imaging on patients with diabetic retinopathy.  Patients will be followed annually for the study.


Studies In Progress (no longer enrolling):

Diabetic Macular Edema / Diabetic Retinopathy Clinical Research Network (PI: Garg)

DRCR T: A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema

This is a 2 year study comparing Aflibercept (Eylea), Bevacizumab (Avastin), and            Ranibizumab (Lucentis) for treatment of Diabetic Macular Edema.  Patients will be          randomly assigned to receive one of the three drugs for the duration of the study.

Primary Open Angle Glaucoma / FSV5-003 (PI: Budenz)

This is a 13 month, open-label follow-up for the subjects that were enrolled in FSV5-002. 

Pilot Study on Ambulatory Intraocular Pressure and Blood Pressure Monitoring in Glaucoma (PI: Mwanza)

This is a 24 hour study to measure blood pressure and eye pressure.  Patients will be expected to wear both devices for the full 24 hours, and return it to the clinic the following day.  20 patients will be recruited through Family Medicine, and 20 patients will be recruited through the UNC Kittner Eye Center Glaucoma clinic.

Primary Open Angle Glaucoma / Aerie Rocket 2 Study (PI: Lawrence)

This is a one year study comparing an investigational drug with currently available therapies.  Patients must participate in a washout period and have an IOP between 20 and 27 mm Hg in order to randomize.